These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16489295)

  • 1. [Molecular mechanisms of anthracyclines action].
    Szuławska A; Czyz M
    Postepy Hig Med Dosw (Online); 2006; 60():78-100. PubMed ID: 16489295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.
    Marinello J; Delcuratolo M; Capranico G
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells.
    Gruber BM; Anuszewska EL; Bubko I; Gozdzik A; Priebe W; Fokt I
    Anticancer Res; 2005; 25(3B):2193-8. PubMed ID: 16158963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L
    Pharmacol Rev; 2004 Jun; 56(2):185-229. PubMed ID: 15169927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline cardiotoxicity.
    Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
    Menna P; Minotti G; Salvatorelli E
    Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracyclines and mitochondria.
    Mordente A; Meucci E; Silvestrini A; Martorana GE; Giardina B
    Adv Exp Med Biol; 2012; 942():385-419. PubMed ID: 22399433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
    Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
    Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structure and activity of anthracyclines].
    Lavelle F
    Pathol Biol (Paris); 1987 Jan; 35(1):11-9. PubMed ID: 3550604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA interactions of 2-pyrrolinodoxorubicin, a distinctively more potent daunosamine-modified analogue of doxorubicin.
    Stepankova J; Studenovsky M; Malina J; Kasparkova J; Liskova B; Novakova O; Ulbrich K; Brabec V
    Biochem Pharmacol; 2011 Aug; 82(3):227-35. PubMed ID: 21570955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
    Vejpongsa P; Yeh ET
    Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems.
    Richardson DS; Johnson SA
    Blood Rev; 1997 Dec; 11(4):201-23. PubMed ID: 9481450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthracyclines: biosynthesis, engineering and clinical applications.
    Hulst MB; Grocholski T; Neefjes JJC; van Wezel GP; Metsä-Ketelä M
    Nat Prod Rep; 2022 Apr; 39(4):814-841. PubMed ID: 34951423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.
    Gruber BM; Anuszewska EL; Bubko I; Goździk A; Fokt I; Priebe W
    Arch Immunol Ther Exp (Warsz); 2007; 55(3):193-8. PubMed ID: 17557149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.
    Kizek R; Adam V; Hrabeta J; Eckschlager T; Smutny S; Burda JV; Frei E; Stiborova M
    Pharmacol Ther; 2012 Jan; 133(1):26-39. PubMed ID: 21839775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
    Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F
    Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.